Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy

Journal of Clinical Virology

Volumn 28, Issue 2, 2003, Pages 186-202

  Sa Filho, Dercy J ^a   Costa, Luciana J ^a   De Oliveira, Carlos F ^a   Guimarães, Ana Paula C ^a   Accetturi, Conceição A ^a   Tanuri, Amilcar ^b   Diaz, Ricardo S ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Genotypic resistance; HIV 1; Indinavir; Protease sequence

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS ENZYME;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME STRUCTURE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; STRUCTURAL GENE; VIRUS GENE; VIRUS LOAD;

EID: 0041920847     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(03)00007-6     Document Type: Article

References (40)

1. Boden D., Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:(11):1998;2775-2783.
2. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:(5197):1995;483-489.
3. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:(6522):1995;569-571.
4. Condra J.H., Holder D.J., Schleif W.A., Blahy O.M., Danovich R.M., Gabryelski L.J., Graham D.J., Laird D., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Yang T., Chodakewitz J.A., Deutsch P.J., Leavitt R.Y., Massari F.E., Mellors J.W., Squires K.E., Steigbigel R.T., Teppler H., Emini E.A. Genetic correlates of in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:(12):1996;8270-8276.
5. Cornelissen M., van den Burg R., Zorgdrager F., Lukashov V., Goudsmit J. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J. Virol. 71:(9):1997;6348-6358.
6. Craig C., Race E., Sheldon J., Whittaker L., Gilbert S., Moffatt A., Rose J., Dissanayeke S., Chirn G.W., Duncan I.B., Cammack N. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. Aids. 12:(13):1998;1611-1618.
7. D'Aquila R.T., Shapiro J.M., Brun-Vezinet F., Clotet B., Conway B., Demeter L.M., Grant R.M., Johnson V.A., Kuritzkes D.R., Loveday C., Shafer R.W., Richman D.D. Drug resistance mutations in HIV-1. Topics in HIV Med. 10:(5):2002;21-25.
8. Erice A., Li W., Balfour H.H. Jr, Boies L.R. Jr, Melroe H., Henry K. Analysis of HIV-1 reverse transcriptase and protease sequences in paired plasma and lymphoid tissue specimens from HIV-1 infected individuals. Aids. 15:(7):2001;831-836.
9. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Jonas L., Meibohm A., Holder D., Schleif W.A., Condra J.H., Emini E.A., Isaacs R., Chodakewitz J.A., Richman D.D. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. J. Am. Med. Assoc. 280:(1):1998;35-41.
10. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron J.J. Jr, Feinberg J.E., Balfour H.H. Jr, Deyton L.R., Chodakewitz J.A., Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New. Engl. J. Med. 337:(11):1997;725-733.
11. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:(6510):1995;123-126.
12. Holland J., Spindler K., Horodyski F., Grabau E., Nichol S., VandePol S. Rapid evolution of RNA genomes. Science. 215:(4540):1982;1577-1585.
13. Ibanez A., Clotet B., Martinez M.A. Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J. Gen. Virol. 81:(Pt 1):2000;85-95.
14. Jetzt A.E., Yu H., Klarmann G.J., Ron Y., Preston B.D., Dougherty J.P. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J. Virol. 74:(3):2000;1234-1240.
15. Kozal M.J., Shah N., Shen N., Yang R., Fucini R., Merigan T.C., Richman D.D., Morris D., Hubbell E., Chee M., Gingeras T.R. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med. 2:(7):1996;753-759.
16. Lech W.J., Wang G., Yang Y.L., Chee Y., Dorman K., McCrae D., Lazzeroni L.C., Erickson J.W., Sinsheimer J.S., Kaplan A.H. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:(3):1996;2038-2043.
17. Loeb D.D., Swanstrom R., Everitt L., Manchester M., Stamper S.E., Hutchison C.A. 3rd. Complete mutagenesis of the HIV-1 protease. Nature. 340:(6232):1989;397-400.
18. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:(8):1995;5087-5094.
19. McKeating J.A., Gow J., Goudsmit J., Pearl L.H., Mulder C., Weiss R.A. Characterization of HIV-1 neutralization escape mutants. Aids. 3:(12):1989;777-784.
20. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G.R., Ho D.D., Boucher C.A., Leonard J.M., Norbeck D.W., Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:(7):1996;760-766.
21. Patick A.K., Duran M., Cao Y., Shugarts D., Keller M.R., Mazabel E., Knowles M., Chapman S., Kuritzkes D.R., Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:(10):1998;2637-2644.
22. Peng C., Ho B.K., Chang T.W., Chang N.T. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63:(6):1989;2550-2556.
23. Pieniazek D., Peralta J.M., Ferreira J.A., Krebs J.W., Owen S.M., Sion F.S., Filho C.F., Sereno A.B., de Sa C.A., Weniger B.G., et al. Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. Aids. 5:(11):1991;1293-1299.
24. Robertson D.L., Hahn B.H., Sharp P.M. Recombination in AIDS viruses. J. Mol. Evol. 40:(3):1995;249-259.
25. Robertson D.L., Sharp P.M., McCutchan F.E., Hahn B.H. Recombination in HIV-1. Nature. 374:(6518):1995;124-126.
26. Ruiz L., Nijhuis M., Boucher C., Puig T., Bonjoch A., Martinez-Picado J., Marfil S., de Jong D., Burger D., Arno A., Balague M., Clotet B. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 19:(1):1998;19-28.
27. Sabino E., Pan L.Z., Cheng-Mayer C., Mayer A. Comparison of in vivo plasma and peripheral blood mononuclear cell HIV-1 quasi-species to short-term tissue culture isolates: an analysis of tat and C2-V3 env regions. Aids. 8:(7):1994;901-909.
28. Sabino E.C., Shpaer E.G., Morgado M.G., Korber B.T., Diaz R.S., Bongertz V., Cavalcante S., Galvao-Castro B., Mullins J.I., Mayer A. Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J. Virol. 68:(10):1994;6340-6346.
29. Sabino E.C., Diaz R.S., Brigido L.F., Learn G.H., Mullins J.I., Reingold A.L., Duarte A.J., Mayer A., Busch M.P. Distribution of HIV-1 subtypes seen in an AIDS clinic in Sao Paulo City, Brazil. Aids. 10:(13):1996;1579-1584.
30. Schapiro J.M., Winters M.A., Stewart F., Efron B., Norris J., Kozal M.J., Merigan T.C. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:(12):1996;1039-1050.
31. Schmidt B., Walter H., Moschik B., Paatz C., van Vaerenbergh K., Vandamme A.M., Schmitt M., Harrer T., Uberla K., Korn K. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. Aids. 14:(12):2000;1731-1738.
32. Schmit J.C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., Vandamme A.M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). Aids. 10:(9):1996;995-999.
33. Simmonds P., Balfe P., Ludlam C.A., Bishop J.O., Brown A.J. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J. Virol. 64:(12):1990;5840-5850.
34. Simmonds P., Balfe P., Peutherer J.F., Ludlam C.A., Bishop J.O., Brown A.J. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J. Virol. 64:(2):1990;864-872.
35. Tanuri A., Vicente A.C., Otsuki K., Ramos C.A., Ferreira O.C. Jr, Schechter M., Janini L.M., Pieniazek D., Rayfield M.A. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrob. Agents Chemother. 43:(2):1999;253-258.
36. Taylor W.R., Jones D.T. Deriving an amino acid distance matrix. J. Theor. Biol. 164:(1):1993;65-83.
37. Thomson M.M., Villahermosa M.L., Vazquez-de-Parga E., Cuevas M.T., Delgado E., Manjon N., Medrano L., Perez-Alvarez L., Contreras G., Carrillo M.G., Salomon H., Najera R. Widespread circulation of a B/F intersubtype recombinant form among HIV-1-infected individuals in Buenos Aires, Argentina. Aids. 14:(7):2000;897-899.
38. Wlodawer A., Miller M., Jaskolski M., Sathyanarayana B.K., Baldwin E., Weber I.T., Selk L.M., Clawson L., Schneider J., Kent S.B. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 245:(4918):1989;616-621.
39. Wolfs T.F., Zwart G., Bakker M., Valk M., Kuiken C.L., Goudsmit J. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology. 185:(1):1991;195-205.
40. Zhang Y.M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., Salzman N.P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:(9):1997;6662-6670.